Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female children and adolescents aged 3 to less than 18 years, at the time of Screening.~* Diagnosis of FXS through molecular documentation of FMR1 full mutation.~* Judged to be in good health based on physical exam, 12-lead ECG and clinical laboratory test results.~* Patients must be assessed by the Investigator as being moderately to severely impacted due to FXS.~* Patients taking psychotropic medication(s) should be on a stable regimen of not more than two such medications for at least fours weeks preceding Screening and must maintain that regimen throughout the study.~* If patients are receiving non-pharmacological, behavioral and/or dietary interventions, they must be stable and have been doing so for three months prior to screening.~* Patients and parents/caregivers must be adequately informed of the nature and risks of the study and given written informed consent prior to Screening.~* In the Investigator's opinion, patients and parents/caregivers are reliable and willing and able to comply with all protocol requirements and procedures.~Exclusion Criteria:~* Females who are pregnant, nursing or planning a pregnancy.~* Alanine aminotransferase (ALT), aspartate aminotransferase (AST) or total bilirubin levels greater than or equal to 2 times the upper limit of normal or alkaline phosphatase levels greater than or equal to 3 times the upper limit of normal.~* Use of a strong inhibitor/inducer of CYP3A4 or sensitive substrate of CYP3A4.~* Use of minocycline for 30 days prior to screening or throughout the study.~* Use of any benzodiazepine at screening or throughout the study.~* Use of THC or CBD-containing product within three months of Screening Visit or during the study.~* Change in pharmacologic or non-pharmacologic intervention during the course of the study.~* Any skin disease or condition including eczema, psoriasis, melanoma, acne, contact dermatitis, scarring, imperfections, lesions, tattoos, or discoloration that may affect treatment application, application site assessments or absorption of the trial drug.~* Patient is using the following ASMs: clobazam, phenobarbital, ethosuximide, felbamate or vigabatrin.~* Patients has an advanced, severe or unstable disease that may interfere with the study outcome evaluations.~* Patient has acute or progressive neurological disease, psychosis, schizophrenia or any other psychiatric disorder or severe mental abnormalities (other than FXS) that are likely to require changes in drug therapy or interfere with the study objectives or ability to adhere to protocol requirements.~* Patient has suspected or confirmed cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, cardiac conduction problems, exercise-related cardiac events including syncope and pre-syncope, risk factors for Torsades de pointes (e.g. heart failure, hypokalemia, family history of Long QT Syndrome) or other serious cardiac problems.~* History of treatment for, or evidence of drug abuse within the past year.~* Patient responds yes to Question 4 or 5 on the C-SSRS (Children) during Screening or at any time on study.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- ZYN002 - Cannabidiol transdermal gel (Type: EXPERIMENTAL): ZYN002 supplied as a transdermal gel. Patients weighing less than or equal to 35 kg will be randomized to receive either 125 mg cannabidiol Q12H or placebo.~Patients weighing greater than 35 kg will be randomized to receive 250 mg cannabidiol Q12H or placebo.
- Placebo transdermal gel (Type: PLACEBO_COMPARATOR): Matching ZYN002 placebo supplied as a transdermal gel.

Based on this trial design, predict the completion outcome and termination type (if applicable).